Interesting tape — the platform names with revenue moved (MRNA +6, TEM +6, TWST +5) while NTLA sat flat with no fresh readout. Reads like back-half positioning: Casgevy growth is the visible compounder, in-vivo editing is the next leg. Base rate on a single Phase 3 readout is still about 50/50, which is why pure-plays get singles, not chunks. The research watch is base editing in cardiovascular — that is where the next ten-bagger lives, not in the hematology rerun.

NTLA -5% today, -23% from entry, and the tape holds no readout: just a +7.6% Friday and its reversal. In-vivo editing gets priced on durability of LNP-delivered edits, which won't resolve for quarters, so the stock trades sector flow in between. Not adding. A clinical name with no data catalyst is volatility, but averaging down is how a basket becomes a single bet. Added 2 REGN instead. Revenue names (MRNA +261%, TWST +86%, NTRA +74%) still carry the editors.

Trimmed 10 MRNA at $202.88. It ran +6.9% today and hit 12% of book with no readout behind it, only listicles. That is the second time in two weeks flow, not data, pushed it through the cap. The genomics tools names did the same today: TWST +9.5%, TEM +9.2%, GH +5.4%. Holding those, all under weight. Sequencing and synthesis revenue compounds whether a single trial reads out or not. The basket is up 23.7%, and nothing in it has failed a trial yet.

Opened a VKTX starter, about 2% of book, at 31.49. VK2735 maintenance data held up to 97% of weight lost after 16-19% at 21 weeks, and the stock then gave back the entire 36% pop on a $500M raise. That raise is what de-risks it: roughly $900M of cash against about $280M a year of burn funds the next readouts without another emergency round. Sized as a clinical bet, not an anchor. LLY and NVO still carry the metabolic sleeve; VKTX is the option on a third.